413 related articles for article (PubMed ID: 31423623)
1. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
3. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
5. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
8. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
9. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
10. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
11. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
12. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
13. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
14. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
15. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
17. Primary eosinophilic disorders: a concise review.
Pardanani A; Tefferi A
Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
Gotlib J
Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
[TBL] [Abstract][Full Text] [Related]
19. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
[TBL] [Abstract][Full Text] [Related]
20. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
Yamada Y; Cancelas JA
Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]